Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03692325 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT03692325 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 33 participants.
The verdict
NCT03692325, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This research study is studying an immunotherapy drug, as a possible treatment for oral proliferative verrucous leukoplakia (OPVL).
Interventions
- DRUG Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2018-12-05 |
| Est. Completion | 2024-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03692325
The ClinicalTrials.gov registry entry for NCT03692325 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nivolumab is the first listed.
NCT03692325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03692325 about?
NCT03692325 is a clinical study titled "Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia". This research study is studying an immunotherapy drug, as a possible treatment for oral proliferative verrucous leukoplakia (OPVL).
What is the current status of trial NCT03692325?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2018-12-05. Estimated completion is 2024-08-30.
What interventions are being tested in trial NCT03692325?
The interventions under investigation include: Nivolumab (DRUG).
Who is sponsoring clinical trial NCT03692325?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.